Archive · 7 Sep 2026
FDA Suspends Kandivali Hospital Blood Centre Licence Pending Appeal
The blood centre at a civic hospital in Kandivali may have to close for three days.
The Maharashtra Food and Drug Administration found several problems during an inspection.
These included unqualified staff testing haemoglobin and incomplete records.
The centre was also operating in only one shift.
The FDA also questioned whether the main doctor met health requirements.
The hospital has appealed the suspension.
It says patients can get blood and blood components from two linked blood banks.
The appeal will decide whether the three-day closure happens in October.
The Maharashtra Food and Drug Administration ordered a three-day suspension of the Kandivali civic hospital blood centre’s licence.
The order followed a March 2, 2026 inspection and was issued on July 27, 2026.
Inspectors cited unqualified haemoglobin-testing personnel, incomplete records, and operation in only one shift.
The FDA also raised concerns about the main doctor’s skin disease under applicable requirements.
The hospital has appealed and says linked blood banks can supply blood and components if the closure proceeds.
- Who
- The Maharashtra Food and Drug Administration and Bharatratna Babasaheb Ambedkar Municipal General Hospital’s administration.
- What
- The FDA ordered a three-day suspension of the hospital blood centre’s licence over reported irregularities; the hospital appealed.
- When
- The inspection occurred on March 2, 2026; the order was issued on July 27, 2026, with implementation planned for three days in mid-October 2026.
- Where
- Bharatratna Babasaheb Ambedkar Municipal General Hospital in Kandivali West, Mumbai.
- Why
- The FDA cited issues including unqualified haemoglobin-testing personnel, incomplete records, single-shift operations, and concerns about the main doctor’s skin disease.
FDA’s findings
Hospital’s response
Licence suspension
FDA’s findings
The FDA ordered a three-day suspension after citing multiple irregularities at the blood centre.
Hospital’s response
The hospital administration appealed the order and is seeking relief from the FDA.
Patient access during closure
FDA’s findings
The suspension could create uncertainty for patients needing blood during surgeries, emergencies, or other critical treatment.
Hospital’s response
The hospital says tie-ups with two other blood banks can provide blood and components at BMC-decided rates if the closure occurs.
- Hospital
- Bharatratna Babasaheb Ambedkar Municipal General Hospital, Kandivali West
- Regulator
- Maharashtra Food and Drug Administration
- Suspension duration
- Three days
- Inspection date
- March 2, 2026
- Suspension letter
- Issued July 27, 2026
- Planned implementation
- Three days in mid-October 2026
- Alternative arrangements
- Tie-ups with two other blood banks for blood and blood components